Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML. Lancet. 2015 Sep 16. pii: S0140-6736(15)00239-1. doi: 10.1016/S0140-6736(15)00239-1. [Epub ahead of print]
Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a team led by his colleagues at the Johns Hopkins University School of Medicine has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by human papillomavirus (HPV).
Read the Department of Communications news release.